Minimally important difference estimates and methods: A protocol by Johnston, Bradley C. et al.
Title Minimally important difference estimates and methods: Aprotocol
Author(s)
Johnston, Bradley C.; Ebrahim, Shanil; Carrasco-Labra,
Alonso; Furukawa, Toshi A.; Patrick, Donald L.; Crawford,
Mark W.; Hemmelgarn, Brenda R.; Schunemann, Holger J.;
Guyatt, Gordon H.; Nesrallah, Gihad
CitationBMJ Open (2015), 5(10)
Issue Date2015-10-01
URL http://hdl.handle.net/2433/216125
Right
This is an Open Access article distributed in accordance with
the Creative Commons Attribution Non Commercial (CC BY-
NC 4.0) license, which permits others to distribute, remix,
adapt, build upon this work non-commercially, and license
their derivative works on different terms, provided the original
work is properly cited and the use is non-commercial.
Type Journal Article
Textversionpublisher
Kyoto University
Minimally important difference
estimates and methods: a protocol
Bradley C Johnston,1,2,3,4 Shanil Ebrahim,1,4,5,6,7 Alonso Carrasco-Labra,4,8
Toshi A Furukawa,9 Donald L Patrick,10 Mark W Crawford,1 Brenda R Hemmelgarn,11
Holger J Schunemann,4,12 Gordon H Guyatt,4,12 Gihad Nesrallah13,14,15
To cite: Johnston BC,
Ebrahim S, Carrasco-Labra A,
et al. Minimally important
difference estimates and
methods: a protocol. BMJ
Open 2015;5:e007953.
doi:10.1136/bmjopen-2015-
007953
▸ Prepublication history
and additional material is
available. To view please visit
the journal (http://dx.doi.org/
10.1136/bmjopen-2015-
007953).
Received 10 April 2015
Revised 21 July 2015
Accepted 31 July 2015
For numbered affiliations see
end of article.
Correspondence to
Dr Gihad Nesrallah;
gnesrallah@hrh.ca
ABSTRACT
Introduction: Patient-reported outcomes (PROs) are
often the outcomes of greatest importance to patients.
The minimally important difference (MID) provides a
measure of the smallest change in the PRO that patients
perceive as important. An anchor-based approach is the
most appropriate method for MID determination. No
study or database currently exists that provides all
anchor-based MIDs associated with PRO instruments;
nor are there any accepted standards for appraising the
credibility of MID estimates. Our objectives are to
complete a systematic survey of the literature to collect
and characterise published anchor-based MIDs
associated with PRO instruments used in evaluating the
effects of interventions on chronic medical and
psychiatric conditions and to assess their credibility.
Methods and analysis: We will search MEDLINE,
EMBASE and PsycINFO (1989 to present) to identify
studies addressing methods to estimate anchor-based
MIDs of target PRO instruments or reporting empirical
ascertainment of anchor-based MIDs. Teams of two
reviewers will screen titles and abstracts, review full
texts of citations, and extract relevant data. On the basis
of findings from studies addressing methods to
estimate anchor-based MIDs, we will summarise the
available methods and develop an instrument
addressing the credibility of empirically ascertained
MIDs. We will evaluate the credibility of all studies
reporting on the empirical ascertainment of anchor-
based MIDs using the credibility instrument, and assess
the instrument’s inter-rater reliability. We will separately
present reports for adult and paediatric populations.
Ethics and dissemination: No research ethics
approval was required as we will be using aggregate
data from published studies. Our work will summarise
anchor-based methods available to establish MIDs,
provide an instrument to assess the credibility of
available MIDs, determine the reliability of that
instrument, and provide a comprehensive compendium
of published anchor-based MIDs associated with PRO
instruments which will help improve the interpretability
of outcome effects in systematic reviews and practice
guidelines.
BACKGROUND
For decades, longevity and major morbid
events (eg, stroke, myocardial infarction)
have been a primary focus in health
research. Increasingly, investigators and clini-
cians have acknowledged the critical role of
disease and treatment-related symptoms, as
well as the function and perceptions of well-
being for informed clinical decision-making.
Typically measured by direct patient inquiry,
these outcomes, previously generally referred
to as ‘quality of life’ or ‘health-related quality
of life’ measures, are now most commonly
referred to as patient-reported outcomes
(PROs). PROs provide patients’ perspectives
on treatment beneﬁts and harms, and are
often the outcomes of most importance to
patients.
The PRO literature has grown exponen-
tially over the past three decades (ﬁgure 1),
with several instruments (eg, Short-Form-36,1
Beck Depression Inventory2) in routine use
in research and clinical practice. The
number of clinical trials evaluating the
impact of interventions on PROs has also
steadily increased (ﬁgure 2), and PROs are
increasingly considered in practice guide-
lines (ﬁgure 3).
Although PROs are often measured as
primary outcomes in clinical trials, chal-
lenges remain in their application. In add-
ition, although evidence supporting
reliability, validity and responsiveness exists
for many PRO instruments, interpretation of
their results remains a challenge.
Interpretability has to do with understand-
ing the changes in instrument scores that
constitute trivial, small but important, moder-
ate or large differences in effect. For
instance, if a treatment improves a PRO score
by three points relative to control, what are
we to conclude? Is the treatment effect large,
warranting widespread dissemination in clin-
ical practice, or is it trivial, suggesting that the
new treatment should be abandoned?
Recognition of this potentially serious limita-
tion has led to increasing interest in the inter-
pretation of treatment effects on PROs.3 4
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The minimally important difference (MID) provides a
measure of the smallest change in the PRO of interest
that patients perceive as important, either beneﬁcial or
harmful, and that would lead the patient or clinician to
consider a change in management.5 Knowledge of the
MID allows decision-makers to better interpret the mag-
nitude of treatment effect and assess the trade-off
between beneﬁcial and harmful outcomes. Patients, clin-
icians and clinical practice guideline developers require
knowledge of the MID to guide their decisions. For
example, a guideline developer using the GRADE
approach6 might consider the MID as a decision thresh-
old for determining if the quality of evidence for a given
intervention should be rated down (for imprecision) if
the CI surrounding a pooled effect estimate includes the
MID,7 or if it is sufﬁciently precise, lying well above the
MID threshold. The MID also provides a metric for clin-
ical trialists planning sample sizes for their studies. This
is accomplished by ﬁrst calculating the proportion of
patients achieving an MID or greater change, and subse-
quently determining the difference in the proportion of
responders that trialists would like to examine between
the treatment and control that would constitute a clinic-
ally important difference. The widespread recognition
of the usefulness of the MID is reﬂected in the exponen-
tial growth in the number of citations reporting MIDs
since the concept was ﬁrst introduced into the medical
literature in 1989 (ﬁgure 4).4
There are two primary approaches for estimating an
MID: distribution-based and anchor-based methods.
Distribution-based methods rely on the distribution
around the mean scores of the measure of interest (eg,
SD).8 In the anchor-based approach, investigators
examine the relation between the target PRO instrument
and an independent measure that is itself interpretable
—the anchor. An appropriate anchor will be relevant to
patients (eg, measures of symptoms, disease severity or
response to treatment).9 Investigators often use global
ratings of change (patients classifying themselves as
unchanged, or experiencing small, moderate and large
improvement or deterioration) as an anchor. It is gener-
ally agreed that the patient-reported anchor-based
Figure 1 Number of citations
found in PubMed with search
terms of patient reported
outcome, by 5-year stratum.
Figure 2 Number of citations
found in PubMed with the search
terms of patient reported outcome
limited to clinical trials, by 5-year
stratum.
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approach is the optimal way to determine the MID
because it directly captures the patients’ preferences and
values,8 10 although it can still be problematic if the cred-
ibility of the anchor is in question (eg, is the anchor itself
interpretable and are responses on the anchor independ-
ent of responses on the PRO?).
Currently, there is no study or database that systematic-
ally documents all available anchor-based MIDs asso-
ciated with PRO instruments. In addition, there are
currently no accepted standards for appraising the cred-
ibility of an MID determination; incorrect methods,
assumptions or interpretation of MID could be detri-
mental to otherwise well-designed clinical trials, system-
atic reviews and guidelines. For example, systematic
review authors and guideline developers might interpret
trials using PROs incorrectly, and provide misleading
guidance to patients and clinicians.11 12 In addition,
erroneous MIDs may lead to inappropriate sample size
calculations.
Our objectives are therefore to:
1. Summarise the anchor-based methods that investiga-
tors have used to estimate MIDs and the criteria thus
far suggested to conduct studies optimally (hence-
forth referred to as a ‘systematic survey addressing
the anchor-based methods used to estimate MIDs’).
2. Develop an instrument for evaluating the credibility of
MIDs that emerge from identiﬁed PRO instruments.
3. Document published anchor-based MIDs associated
with PRO instruments used in evaluating the effects
of interventions on chronic medical and psychiatric
conditions in adult and paediatric populations
(henceforth referred to as a ‘systematic survey of the
inventory of published anchor-based MIDs’).
4. Apply the credibility criteria (developed in objective
2) to each of the MID estimates that emerge from
our synthesis in objective 3.
5. Determine the reliability of our credibility instrument
(developed in objective 2).
Figure 3 Number of citations
found in PubMed with search
terms of patient reported outcome
and practice guidelines, by 5-year
strata.
Figure 4 Number of citations
found in PubMed with search
terms of minimal (clinically)
important difference, by 5-year
stratum.
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To ensure the feasibility and a manageable scope of
the project and given that the primary use of PROs is in
the management of chronic medical and psychiatric
conditions,13 we have restricted our focus to these clin-
ical areas.
METHODS
Eligibility criteria
We deﬁne an anchor-based approach as any independ-
ent assessment to which the PRO instrument is com-
pared, irrespective of the interpretability or the quality
of the anchor. We will include two types of publications:
(1) Methods articles addressing MID estimation using
an anchor-based approach (theoretical descriptions,
summaries, commentaries, critiques). We will include
only studies that dedicate a minimum of two paragraphs
to discuss methodological issues when estimating MIDs
from both of these types of studies. (2) Original reports
of studies that document the empirical development of
an anchor-based MID for a particular instrument in a
wide range of chronic medical and psychiatric condi-
tions. That is, studies will compare the results of a PRO
instrument to an independent standard (the ‘anchor’),
irrespective of the interpretability or the quality of the
anchor. We will include adult (≥18 years of age) and
paediatric populations (<18 years of age). PROs of inter-
est will include self-reported patient-important outcomes
of health-related quality of life, functional ability,
symptom severity and measures of psychological distress
and well-being.
In our deﬁnition of a PRO, if the patient is incapable
of responding to the instrument and a proxy is used,
then the study is still eligible. If the clinician completes
only the anchor, then it is still eligible. For anchor-based
MIDs identiﬁed in the paediatric population for chil-
dren under the age of 13, we will include both patient-
reported and caregiver-reported instruments.
We will exclude studies when only the clinician com-
pletes the PRO instrument (ineligible proxy), as well as
studies reporting only distribution-based MIDs without
an accompanying anchor-based MID.
Information sources and search
We will search MEDLINE, EMBASE and PsycINFO for
studies published from 1989 to the present (the MID
concept was ﬁrst introduced into the medical literature
in 1989).3 Search terms will include database subject
headings and text words for the concepts: ‘minimal
important difference’, ‘minimal clinical important differ-
ence’, ‘clinically important difference’, ‘minimal import-
ant change’, alone and in combination, and adapted for
each of the chosen databases. Table 1 presents the
MEDLINE search strategy. One of the co-authors (DLP)
works closely with MAPI Trust, which maintains
PROQOLID—a large repository of commonly used, well-
validated PRO instruments.13 To supplement our search,
the investigator has granted us access to the PROQOLID
internal library, which houses approximately 180 cita-
tions related to MID estimates. We will, in addition,
search the citation lists of included studies and collect
narrative and systematic reviews for original studies that
report an MID for a given instrument.
Study selection
Teams of two reviewers will independently screen titles
and abstracts to identify potentially eligible citations. To
determine eligibility, the same reviewers will review the
full texts of citations ﬂagged as potentially eligible.
Data collection, items and extraction
Teams of data extractors will, independently and in
duplicate, extract data using two pilot-tested data collec-
tion forms: one for the systematic survey addressing the
anchor-based methods used to estimate MIDs, and the
second for the systematic survey of the inventory of pub-
lished anchor-based MIDs. On study initiation, we will
conduct calibration exercises until sufﬁcient agreement
is achieved. Our data collection forms will include the
following items: study design, description of population,
interventions, outcomes, characteristics of candidate
instruments (eg, generic or disease speciﬁc), character-
istics of independent anchor measures, critiques/com-
mentary on methods to estimate MID(s), and credibility
criteria for method(s) to estimate MIDs.
For the extraction of anchor-based methods studies
used to estimate MIDs, a team of methodologists famil-
iar with MID methods will use standard thematic analysis
techniques14 to abstract concepts related to the meth-
odological quality of MID determinations until reaching
saturation. We will review coding and revise the tax-
onomy of methodological factors iteratively until infor-
mational redundancy is achieved. Appendix A presents
the data extraction items for the systematic survey of the
inventory of published anchor-based MIDs. Reviewers
will resolve disagreements by discussion and, if needed,
a third team member will serve as an adjudicator.
Subsequently, we will synthesise and complete each
objective as follows:
OBJECTIVE 1: METHODS TO DEVELOP ANCHOR-BASED
METHODS USED TO ESTIMATE MIDS
We will classify the anchor-based approaches used to
determine MIDs into separate categories, describe their
methods, and summarise their advantages, disadvantages
and important factors that constitute a high-quality
anchor.
OBJECTIVE 2: DEVELOPMENT OF A CREDIBILITY
INSTRUMENT FOR STUDIES DETERMINING MIDS
We deﬁne credibility as the extent to which the design
and conduct of studies measuring MIDs are likely to
have protected against misleading estimates. Similar deﬁ-
nitions have been used for instruments measuring the
credibility of other types of study designs.15 16
4 Johnston BC, et al. BMJ Open 2015;5:e007953. doi:10.1136/bmjopen-2015-007953
Open Access
group.bmj.com on July 28, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
The systematic survey addressing methods to estimate
MIDs (objective 1) will identify all the available method-
ologies and concepts along with their strengths and lim-
itations, and will thus inform the item generation stage
of instrument development. On the basis of the survey
of the methods literature and our group’s experience
with methods of ascertaining MIDs,3 4 17–22 we will
develop initial criteria for evaluating the credibility of
anchor-based MID determinations. Our group has used
these methods successfully for developing methodo-
logical quality appraisal standards across a wide range of
topics.16 23–26
Using a sample of eligible studies, we will pilot the
draft instrument with four target users, speciﬁcally
researchers interested in the credibility of MID esti-
mates, who will be identiﬁed within our international
network of knowledge users (please see ‘Knowledge
Translation’ section below). The data collected at this
stage will inform item modiﬁcation and reduction. This
iterative process will be conducted until we achieve con-
sensus for the ﬁnal version of the instrument.
OBJECTIVE 3: SYSTEMATIC SURVEY OF STUDIES
GENERATING AN ANCHOR-BASED MID OF TARGET PRO
INSTRUMENTS
We will summarise MID estimates separately for paediat-
ric and adult populations, along with study design, inter-
vention, population characteristics, characteristics of the
PRO, characteristics of the anchor and credibility
ratings. If multiple MID estimates are captured for the
same PRO instrument across similar clinical conditions,
we will summarise all the estimates.
OBJECTIVE 4: MEASURING CREDIBILITY OF
COMPILED MIDS
Using the instrument (the development of which we
have described in objective 2), teams of two reviewers
will undertake the credibility assessment for all eligible
studies identiﬁed in the review. The appraisal will be per-
formed in duplicate, using prepiloted forms.
Disagreements will be resolved by discussion between
the reviewers and, if needed, with a third team member.
Table 1 Search strategies for MEDLINE, January 1989 to present
1 (clinical* important difference? or clinical* meaningful difference? or clinical* meaningful improvement? or clinical*
relevant mean difference? or clinical* significant change? or clinical* significant difference? or clinical* important
improvement? or clinical* meaningful change? or mcid or minim* clinical* important or minim* clinical* detectable or
minim* clinical* significant or minim* detectable difference? or minim* important change? or minim* important difference?
or smallest real difference? or subjectively significant difference?).tw.
2 “Quality of Life”/
3 “outcome assessment(health care)”/or treatment outcome/or treatment failure/
4 exp pain/
5 exp disease attributes/or exp “signs and symptoms”/
6 or/2–5
7 1 and 6
8 health status indicators/or “severity of illness index”/or sickness impact profile/or interviews as topic/or questionnaires/
or self report/
9 Pain Measurement/
10 patient satisfaction/or patient preference/
11 or/8–10
12 7 and 11
13 limit 12 to yr=“1989 -Current”
14 (quality of life or life qualit??? or hrqol or hrql).mp.
15 (assessment? outcome? or measure? outcome? or outcome? studies or outcome? study or outcome? assessment? or
outcome? management or outcome? measure* or outcome? research or patient? outcome? or research outcome? or
studies outcome? or study outcome? or therap* outcome? or treatment outcome? or treatment failure?).mp.
16 pain????.mp.
17 ((activity or sever* or course) adj3 (disease or disabilit* or symptom*)).mp.
18 or/14–17
19 1 and 18
20 (questionnaire? or instrument? or interview? or inventor* or test??? or scale? or subscale? or survey? or index?? or
indices or form? or score? or measurement?).mp.
21 (patient? rating? or subject* report? or subject* rating? or self report* or self evaluation? or self appraisal? or self assess*
or self rating? or self rated).mp.
22 (patient? report* or patient? observ* or patient? satisf*).mp.
23 anchor base??.mp.
24 or/20–23
25 19 and 24
26 limit 25 to yr=“1989 -Current”
27 13 or 26
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Knowledge users (eg, future systematic review authors or
guideline developers) could then use their judgement
to consider the credibility of the MID on a continuum
from ‘highly credible’ to ‘very unlikely to be credible’.
OBJECTIVE 5: RELIABILITY STUDY OF THE CREDIBILITY
INSTRUMENT
We will conduct a reliability study of our instrument to
measure the credibility of MIDs by calculating the inter-
rater reliability and associated 95% CI as measured by
weighted κ with quadratic weights. We will complete reli-
ability analyses using classical test theory. We will con-
sider a reliability coefﬁcient of at least 0.7 to represent
‘good’ inter-rater reliability.27–29 According to Walter
et al,30 considering three replicates per study (three
raters), a minimally acceptable level of reliability of 0.6
and an expected reliability of 0.7, an α of 0.05 and a
β of 0.2, we would require a minimum of 133 observa-
tions/study assessed per rater. We will use all the studies
identiﬁed in the systematic survey of estimated MIDs to
calculate the reliability estimate. On the basis of initial
pilot screening, we estimate that we will have approxi-
mately 400 eligible studies.
KNOWLEDGE TRANSLATION
Our multidisciplinary study team is composed of knowl-
edge users and researchers with a broad range of
content and methodological expertise. We represent
and provide direct links to international networks of key
knowledge users including the GRADE Working Group,
the Cochrane Collaboration, the WHO and the
Canadian Agency for Drugs and Technologies in Health.
Collectively, these organisations provide opportunities
for disseminating our ﬁndings to an international
network of clinical trialists, systematic review authors,
guideline developers and researchers involved in the
development of PROs.
Our dissemination strategies include the incorporation
of our knowledge products into Cochrane reviews via
the GRADEproﬁler (http://www.guidelinedevelopment.
org—a globally-adopted platform that is widely used by
our target audience for conducting systematic reviews
and developing practice guidelines) and MAGICapp (a
guideline and evidence summary creation tool that uses
the GRADE framework). We will offer our work for rele-
vant portions of the printed and online versions of the
Cochrane Handbook, and we will develop interactive
education sessions (workshops) and research briefs to
inform knowledge-users from various health disciplines
about our ﬁndings and their implications for clinical
trial, systematic review and guideline development.
DISCUSSION
Our systematic survey will represent the ﬁrst overview of
methods to develop anchor-based MIDs, and the ﬁrst
comprehensive compendium of published anchor-based
MIDs associated with PRO instruments used in evaluat-
ing the effects of interventions on chronic medical and
psychiatric conditions. Our systematic survey on methods
to estimate MIDs will draw attention to the methodo-
logical issues and challenges involved in MID determina-
tions. In doing so, we will deepen the understanding
and improve the quality of reporting and use of MIDs by
our target knowledge users. The methods review will
inform the development of an instrument to determine
the credibility of anchor-based MIDs that will allow us to
address existing MIDs and can subsequently be used to
evaluate new studies offering anchor-based MIDs. This
work will also help knowledge users identify anchor-
based MIDs that may be less credible, misleading or
inappropriate with respect to the average magnitude of
change that is important to patients.
We recognise that some variability in MIDs will be
attributable to context and patient characteristics. For
example, anchor-based MIDs are established using
average magnitudes of change that are considered
important to patients. Without individual patient data,
we will not be able to explore, for example, subgroups of
patients with mild or severe disease, gender differences
and the relative contributions of these factors. We will
alert our knowledge users to this potential limitation.
Collectively, these efforts will promote better-informed
decision-making by clinical trialists, systematic review
authors, guideline developers and clinicians interpreting
treatment effects on PROs.
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